Arioka Masaki, Takahashi-Yanaga Fumi, Kubo Momoko, Igawa Kazunobu, Tomooka Katsuhiko, Sasaguri Toshiyuki
Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Pharmacology, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan.
Biochem Pharmacol. 2017 Aug 15;138:31-48. doi: 10.1016/j.bcp.2017.05.004. Epub 2017 May 10.
Differentiation-inducing factor-1 (DIF-1) isolated from Dictyostelium discoideum strongly inhibits the proliferation of various mammalian cells through the activation of glycogen synthase kinase-3 (GSK-3). To evaluate DIF-1 as a novel anti-cancer agent for malignant melanoma, we examined whether DIF-1 has anti-proliferative, anti-migratory, and anti-invasive effects on melanoma cells using in vitro and in vivo systems. DIF-1 reduced the expression levels of cyclin D1 and c-Myc by facilitating their degradation via GSK-3 in mouse (B16BL6) and human (A2058) malignant melanoma cells, and thereby strongly inhibited their proliferation. DIF-1 suppressed the canonical Wnt signaling pathway by lowering the expression levels of transcription factor 7-like 2 and β-catenin, key transcription factors in this pathway. DIF-1 also inhibited cell migration and invasion, reducing the expression of matrix metalloproteinase-2; however, this effect was not dependent on GSK-3 activity. In a mouse lung tumor formation model, repeated oral administrations of DIF-1 markedly reduced melanoma colony formation in the lung. These results suggest that DIF-1 inhibits cell proliferation by a GSK-3-dependent mechanism and suppresses cell migration and invasion by a GSK-3-independent mechanism. Therefore, DIF-1 may have a potential as a novel anti-cancer agent for the treatment of malignant melanoma.
从盘基网柄菌中分离出的分化诱导因子-1(DIF-1)通过激活糖原合酶激酶-3(GSK-3)强烈抑制各种哺乳动物细胞的增殖。为了评估DIF-1作为恶性黑色素瘤新型抗癌剂的作用,我们使用体外和体内系统研究了DIF-1对黑色素瘤细胞是否具有抗增殖、抗迁移和抗侵袭作用。DIF-1通过促进小鼠(B16BL6)和人(A2058)恶性黑色素瘤细胞中细胞周期蛋白D1和c-Myc经GSK-3介导的降解,降低其表达水平,从而强烈抑制它们的增殖。DIF-1通过降低该途径中的关键转录因子转录因子7样2和β-连环蛋白的表达水平,抑制经典Wnt信号通路。DIF-1还抑制细胞迁移和侵袭,降低基质金属蛋白酶-2的表达;然而,这种作用不依赖于GSK-3活性。在小鼠肺肿瘤形成模型中,重复口服DIF-1可显著减少肺中黑色素瘤集落的形成。这些结果表明,DIF-1通过GSK-3依赖性机制抑制细胞增殖,并通过GSK-3非依赖性机制抑制细胞迁移和侵袭。因此,DIF-1可能具有作为治疗恶性黑色素瘤新型抗癌剂的潜力。